Literature DB >> 28601291

Absence of autoreactive CD4+ T-cells targeting HLA-DQA1*01:02/DQB1*06:02 restricted hypocretin/orexin epitopes in narcolepsy type 1 when detected by EliSpot.

Birgitte Rahbek Kornum1, Kristoffer Sølvsten Burgdorf2, Anja Holm3, Henrik Ullum4, Poul Jennum5, Stine Knudsen6.   

Abstract

Narcolepsy type 1, a neurological sleep disorder strongly associated with Human Leukocyte Antigen (HLA-)DQB1*06:02, is caused by the loss of hypothalamic neurons producing the wake-promoting neuropeptide hypocretin (hcrt, also known as orexin). This loss is believed to be caused by an autoimmune reaction. To test whether hcrt itself could be a possible target in the autoimmune attack, CD4+ T-cell reactivity towards six different 15-mer peptides from prepro-hypocretin with high predicted affinity to the DQA1*01:02/DQB1*06:02 MHC class II dimer was tested using EliSpot in a cohort of 22 narcolepsy patients with low CSF hcrt levels, and 23 DQB1*06:02 positive healthy controls. Our ELISpot assay had a detection limit of 1:10,000 cells. We present data showing that autoreactive CD4+ T-cells targeting epitopes from the hcrt precursor in the context of MHC-DQA1*01:02/DQB1*06:02 are either not present or present in a frequency is <1:10,000 among peripheral CD4+ T-cells from narcolepsy type 1 patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD4(+) T-cells; ELISpot; HLA-DQ; Hypocretin; Narcolepsy; Orexin

Mesh:

Substances:

Year:  2017        PMID: 28601291     DOI: 10.1016/j.jneuroim.2017.05.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  T cells in patients with narcolepsy target self-antigens of hypocretin neurons.

Authors:  Daniela Latorre; Ulf Kallweit; Eric Armentani; Mathilde Foglierini; Federico Mele; Antonino Cassotta; Sandra Jovic; David Jarrossay; Johannes Mathis; Francesco Zellini; Burkhard Becher; Antonio Lanzavecchia; Ramin Khatami; Mauro Manconi; Mehdi Tafti; Claudio L Bassetti; Federica Sallusto
Journal:  Nature       Date:  2018-09-19       Impact factor: 49.962

Review 2.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

3.  Widespread Tau-Specific CD4 T Cell Reactivity in the General Population.

Authors:  Cecilia S Lindestam Arlehamn; John Pham; Roy N Alcalay; April Frazier; Evan Shorr; Chelsea Carpenter; John Sidney; Rekha Dhanwani; Julian Agin-Liebes; Francesca Garretti; Amy W Amara; David G Standaert; Elizabeth J Phillips; Simon A Mallal; Bjoern Peters; David Sulzer; Alessandro Sette
Journal:  J Immunol       Date:  2019-05-13       Impact factor: 5.422

Review 4.  The neurobiological basis of narcolepsy.

Authors:  Carrie E Mahoney; Andrew Cogswell; Igor J Koralnik; Thomas E Scammell
Journal:  Nat Rev Neurosci       Date:  2019-02       Impact factor: 34.870

Review 5.  Hypocretin as a Hub for Arousal and Motivation.

Authors:  Susan M Tyree; Jeremy C Borniger; Luis de Lecea
Journal:  Front Neurol       Date:  2018-06-06       Impact factor: 4.003

Review 6.  Advances of Single-Cell Protein Analysis.

Authors:  Lixing Liu; Deyong Chen; Junbo Wang; Jian Chen
Journal:  Cells       Date:  2020-05-20       Impact factor: 6.600

7.  Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy.

Authors:  Guo Luo; Aditya Ambati; Ling Lin; Mélodie Bonvalet; Markku Partinen; Xuhuai Ji; Holden Terry Maecker; Emmanuel Jean-Marie Mignot
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-12       Impact factor: 11.205

8.  A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis.

Authors:  Alexander Lind; Ilaria Marzinotto; Cristina Brigatti; Anita Ramelius; Lorenzo Piemonti; Vito Lampasona
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 9.  Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know.

Authors:  Lois E Krahn; Phyllis C Zee; Michael J Thorpy
Journal:  Adv Ther       Date:  2021-12-11       Impact factor: 3.845

10.  Characterization of T cell receptors reactive to HCRTNH2, pHA273-287, and NP17-31 in control and narcolepsy patients.

Authors:  Guo Luo; Jing Zhang; Ling Lin; Emmanuel Jean-Marie Mignot
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.